[ad_1]
Although influenza is, in most cases, a minor transient illness, some populations, such as the elderly or those with impaired immunity, have an increased risk of developing infection and the disease is complicated and is more likely to respond poorly to vaccination
The disease itself is highly variable and, therefore, vaccines need to be combined with specific strains of virus that circulate in each growing season. influenza. Many of the large-scale neutralizing antibody (bnAb) treatments have been unsuccessful, partly because of a similar lack of coverage between influenza A and B virus strains and the need for multiple injections at high dose protection Now a team of researchers has discovered in the flames a specific type of antibody capable of acting against several strains of the influenza virus . Although the procedure was only tested on mice, his results, published in Science, are very promising.
Although vaccines are currently the most widely used tool for the management and prevention of epidemics in the world, their effectiveness between seasons and populations remains limited. The new discovery looks promising as a preventative measure that could be immediately effective early in an epidemic.
— Including Avian Influenza —
Researchers led by Nick Laursen, Scripps Research Institute in La Jolla, California (USA), generated a new anti-influenza antibody which provides lasting and universal protection against a wide variety of influenza A and B viruses, including avian transmission strains such as H1N1 Depending on the results, the onset of complete protection against influenza may quickly provide protection for a whole season, especially in the elderly or immunocompromised.
Scientists are looking to put in place a long-lasting protection against the flu. Influenza virus based on widely isolated isolated single-domain antibodies (sdAb) immunized with influenza vaccines. From these SDAbs, the authors generated a highly potent multi-domain antibody (MDAb) antibody that can be targeted to several epitopes of antigens, called MD3606.
In mice treated intranasally Adenovirus, the antibodies provided almost universal protection against influenza A and B viruses. In addition, it has been shown that aged and immunodeficient animals were protected against lethal doses of influenza. avian H1N1. The researchers conclude that if these preclinical results are translated into humans, we could be faced with a powerful tool for the fight against influenza in vulnerable populations currently unvaccinated by traditional vaccination.
Source: N + 1
Follow us on Twitter …
Source link
